Terms: = Ovarian cancer AND KEAP1, INrf2, ENSG00000079999, 9817, Q14145, MGC9454, MGC4407, MGC20887, MGC1114, MGC10630, KLHL19, KIAA0132 AND Prognosis
4 results:
1. CCRK is a novel signalling hub exploitable in cancer immunotherapy.
Mok MT; Zhou J; Tang W; Zeng X; Oliver AW; Ward SE; Cheng AS
Pharmacol Ther; 2018 Jun; 186():138-151. PubMed ID: 29360538
[TBL] [Abstract] [Full Text] [Related]
2. Expression Patterns of Nrf2 and keap1 in ovarian cancer Cells and their Prognostic Role in Disease Recurrence and Patient Survival.
Cho HY; Kim K; Kim YB; Kim H; No JH
Int J Gynecol Cancer; 2017 Mar; 27(3):412-419. PubMed ID: 28129239
[TBL] [Abstract] [Full Text] [Related]
3. Prognostic and predictive values of Nrf2, keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma.
Liew PL; Hsu CS; Liu WM; Lee YC; Lee YC; Chen CL
Int J Clin Exp Pathol; 2015; 8(5):5642-9. PubMed ID: 26191276
[TBL] [Abstract] [Full Text] [Related]
4. A new prognostic index model using meta-analysis in early-stage epithelial ovarian cancer.
Park HJ; Nam EJ; Rha SY; Kim S; Kim SW; Kim JW; Kim YT
Gynecol Oncol; 2012 Sep; 126(3):357-63. PubMed ID: 22687686
[TBL] [Abstract] [Full Text] [Related]
